Acknowledgements: CRAM: Research Ireland: 13/RC/2073_P2, SENSOME Disclosure of interest: All authors:nothing to disclose Poster session I - DIAGNOSIS / ETIOLOGY 04.00 - DIAGNOSIS / ETIOLOGY - 04.01 - DIAGNOSIS/INVESTIGATION OF STROKE ETIOLOGY P349 - ESOC25-2048 ELECTRICAL IMPEDANCE SIGNATURES OF RED BLOOD CELLS AND PLATELETS IN ACUTE ISCHEMIC STROKE (AIS) CLOTS OFFER INSIGHTS INTO ETIOLOGY AND FIRST-PASS EFFECT Cansu Sahin 1,2 , Alice Giraud 3 , Nazan Guner Sak 1,2 , Wenyi Liu 1 , Pierluca Messina 3 , Franz Bozsak 3 , Jean Darcourt 4,5 , Juega Jess 6 , Tsuyoshi Ohta 7 , Vanessa Chalumeau 8 , Ivan Vukasinovic 9 , Marc Ribo 6 , Nobuyuki Sakai 7 , Christophe Cognard 4 , Karen Doyle 1,2 1 Department of Physiology, University of Galway, Galway, Ireland, Galway, Ireland, 2 CRAM Research Ireland Centre for Medical Devices, University of Galway, Galway, Ireland, Galway, Ireland, 3 Sensome, Massy, France, Massy, France, 4 Department of Diagnostic and Therapeutic Neuroradiology, CHU de Toulouse, Toulouse, France, Toulouse, France, 5 Radiology department, Ramsay Sant Clinique des Cdres, Cornebarrieu, France, Cornebarrieu, France, 6 Department of Neurology, University Hospital Vall dHebron, Barcelona, Spain, Barcelona, Spain, 7 Department of Neurosurgery, Kobe City Medical Center General Hospital, Kobe, Japan, Kobe, Japan, 8 Bictre Hospital, Department of Interventional Neuroradiology, Le Kremlin-Bictre, France, Le Kremlin-Bictre, France, 9 Center for Radiology and MRI, Clinic for Neurosurgery, University Clinical Center of Serbia, Belgrade, Serbia, Belgrade, Serbia Background and Aims: Electrical impedance signatures may help characterize clot composition in AIS patients, providing neurointerventionalists with insights to inform AIS treatment
2-py, N1-methyl-2-pyridone-5-carboxamide
Many cardiac, vascular, hematologic, autoimmune, neurological, and reproductive problems can be triggered by either the modified mRNA inoculations or coronavirus infections, or both
A provider can help review: Whether BPC-157 is appropriate for your situation Whether another peptide or regenerative option may be safer Possible medication or health-history concerns Route of use and cycle length Sterility and sourcing concerns Whether follow-up monitoring is needed When to stop, pause, or adjust the plan Medical guidance matters because peptide therapy should be personalized, monitored, and tied to a real treatment goal
